DisclosureWe earn commission on partner links; ranking is set by clinician-vetted methodology — not advertisers.
Every Tuesday: new product reviews, price drops, FDA actions, and the latest peer-reviewed research distilled. One email — under 5 minutes to read.
Eli Lilly joins TrumpRx with Zepbound + Mounjaro at $549/mo cash. Plus: FDA Q1 enforcement actions, Hims settlement aftermath, and three new compounders we are watching.
Read this issue →The 28-month Wegovy shortage ended this week. Compounders now face 60-day wind-down. What this means for the ~1.2M patients on compounded semaglutide — and your prescription path forward.
Read this issue →Medicare Part D will cover Wegovy for obesity starting July 1, 2026 — but with strict prior auth. We obtained the draft PA criteria and walked our medical board through every line.
Read this issue →